Lindner Center of HOPE, Mason, Ohio; Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Int J Eat Disord. 2013 Nov;46(7):747-50. doi: 10.1002/eat.22159. Epub 2013 Jul 25.
To assess preliminarily the effectiveness of zonisamide in bulimia nervosa.
This was an open-label, prospective, 12-week, flexible dose study of zonisamide in bulimia nervosa. The primary outcome was binge-purge episode frequency.
Twelve individuals received zonisamide, 10 completed at least one post-baseline evaluation, and six completed the study. Mean dose at endpoint was 420 (SD = 215) mg/day. Zonisamide was associated with significant reductions in frequency of binge-purge episodes and binge-purge days as well as measures of binge eating behavior, purging behavior, clinical severity, obsessive-compulsive features, and depressive symptoms. Weight was unchanged.
In this open-label trial, zonisamide was effective in bulimia nervosa, but associated with a high discontinuation rate.
初步评估佐米曲普坦治疗神经性贪食症的疗效。
这是一项为期 12 周、开放标签、前瞻性、灵活剂量的佐米曲普坦治疗神经性贪食症的研究。主要结局指标为暴食-清除发作频率。
12 名患者接受了佐米曲普坦治疗，其中 10 名至少完成了一次基线后评估，6 名完成了研究。终点时的平均剂量为 420（SD=215）mg/天。佐米曲普坦与暴食-清除发作频率和暴食-清除天数以及暴食行为、清除行为、临床严重程度、强迫特征和抑郁症状的显著减少相关。体重无变化。
在这项开放标签试验中，佐米曲普坦对神经性贪食症有效，但停药率较高。
